Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Jordan J,Feld

第一单位： Toronto Centre for Liver Disease, University of Toronto, Ontario.

作者： Jordan J,Feld ^[1] ; Alnoor,Ramji ^[2] ; Stephen D,Shafran ^[3] ; Bernard,Willems ^[4] ; Paul,Marotta ^[5] ; Emmanuelle,Huchet ^[6] ; Marie-Louise,Vachon ^[7] ; Evguenia S,Svarovskaia ^[8] ; K C,Huang ^[8] ; Robert H,Hyland ^[8] ; Chohee,Yun ^[8] ; Benedetta,Massetto ^[8] ; Diana M,Brainard ^[8] ; John G,McHutchison ^[8] ; Edward,Tam ^[9] ; Robert,Bailey ^[10] ; Curtis,Cooper ^[11] ; Eric M,Yoshida ^[12] ; Susan,Greenbloom ^[13] ; Magdy,Elkhashab ^[14] ; Sergio,Borgia ^[15] ; Mark G,Swain ^[16]

作者单位： Toronto Centre for Liver Disease, University of Toronto, Ontario. ^[1] GI Research Institute, Vancouver, British Columbia. ^[2] University of Alberta, Edmonton. ^[3] Centre hospitalier de l'Université de Montréal, Quebec. ^[4] London Health Sciences Centre, Ontario. ^[5] Clinique médicale l'Actuel, Montreal, Quebec. ^[6] CHU de Québec-Université Laval, Canada. ^[7] Gilead Sciences, Inc, Foster City, California. ^[8] LAIR Centre, Vancouver, British Columbia. ^[9] GI Research, Edmonton, Alberta. ^[10] Ottawa Hospital Research Institute, Ontario. ^[11] Vancouver General Hospital, British Columbia. ^[12] Toronto Digestive Disease Associates Inc, Vaughan. ^[13] Toronto Liver Centre. ^[14] William Osler Health System, Toronto, Ontario. ^[15] University of Calgary, Alberta, Canada. ^[16]

关键词 NS5A NS5B genotype 3 hepatitis C virus